Latest Insider Transactions at Exagen Inc. (XGN)
This section provides a real-time view of insider transactions for Exagen Inc. (XGN). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of EXAGEN INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of EXAGEN INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 16
2024
|
John Aballi President and CEO |
BUY
Open market or private purchase
|
Indirect |
40,401
+50.0%
|
$40,401
$1.92 P/Share
|
|
Mar 04
2024
|
Kamal Adawi CFO and Corporate Secretary |
SELL
Open market or private sale
|
Direct |
12,784
-2.52%
|
$12,784
$1.91 P/Share
|
|
Feb 29
2024
|
John Aballi President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
9,804
+1.61%
|
$9,804
$1.91 P/Share
|
|
Feb 20
2024
|
John Aballi President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
175,000
+22.85%
|
-
|
|
Feb 20
2024
|
Kamal Adawi CFO and Corporate Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+22.62%
|
-
|
|
Feb 06
2024
|
Kamal Adawi CFO and Corporate Secretary |
SELL
Open market or private sale
|
Direct |
6,738
-3.58%
|
$6,738
$1.95 P/Share
|
|
Oct 17
2023
|
John Aballi President and CEO |
SELL
Open market or private sale
|
Direct |
33,819
-7.52%
|
$33,819
$1.75 P/Share
|
|
Aug 31
2023
|
John Aballi President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
9,803
+2.13%
|
$19,606
$2.14 P/Share
|
|
Jun 15
2023
|
James L L Tullis > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
167
+0.01%
|
$501
$3.11 P/Share
|
|
Mar 02
2023
|
Kamal Adawi CFO and Corporate Secretary |
SELL
Open market or private sale
|
Direct |
3,667
-1.91%
|
$7,334
$2.3 P/Share
|
|
Mar 02
2023
|
Mark Hazeltine Chief Business Officer |
SELL
Open market or private sale
|
Direct |
3,667
-1.89%
|
-
|
|
Feb 27
2023
|
Mark Hazeltine Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+34.03%
|
-
|
|
Feb 27
2023
|
Kamal Adawi CFO and Corporate Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+34.25%
|
-
|
|
Feb 08
2023
|
Kamal Adawi CFO and Corporate Secretary |
SELL
Open market or private sale
|
Direct |
5,821
-5.95%
|
$11,642
$2.69 P/Share
|
|
Feb 08
2023
|
Mark Hazeltine Chief Business Officer |
SELL
Open market or private sale
|
Direct |
5,821
-5.84%
|
$11,642
$2.69 P/Share
|
|
Dec 08
2022
|
John Aballi President and CEO |
BUY
Open market or private purchase
|
Direct |
90,000
+16.98%
|
$180,000
$2.68 P/Share
|
|
Oct 16
2022
|
John Aballi President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
350,000
+50.0%
|
-
|
|
Mar 01
2022
|
Fortunato R. Rocca President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,322
-3.46%
|
$30,254
$7.12 P/Share
|
|
Mar 01
2022
|
Kamal Adawi CFO and Corporate Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
3,241
-3.21%
|
$22,687
$7.12 P/Share
|
|
Mar 01
2022
|
Mark Hazeltine Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,241
-3.15%
|
$22,687
$7.12 P/Share
|
|
Mar 01
2022
|
Debra Zack Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,241
-3.7%
|
$22,687
$7.12 P/Share
|
|
Feb 04
2022
|
Fortunato R. Rocca President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+37.5%
|
-
|
|
Feb 04
2022
|
Kamal Adawi CFO and Corporate Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
63,500
+38.6%
|
-
|
|
Feb 04
2022
|
Mark Hazeltine Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
63,500
+38.15%
|
-
|
|
Feb 04
2022
|
Debra Zack Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+36.36%
|
-
|
|
Sep 03
2021
|
Wendy S. Johnson Director |
BUY
Open market or private purchase
|
Direct |
1,000
+50.0%
|
$14,000
$14.02 P/Share
|
|
Aug 05
2021
|
James L L Tullis > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
6,800
-0.45%
|
$68,000
$10.72 P/Share
|
|
Aug 04
2021
|
James L L Tullis > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
2,100
-0.14%
|
$23,100
$11.39 P/Share
|
|
Aug 03
2021
|
James L L Tullis > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
4,300
-0.28%
|
$47,300
$11.77 P/Share
|
|
Aug 02
2021
|
James L L Tullis > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
1,800
-0.12%
|
$19,800
$11.92 P/Share
|
|
Jun 29
2021
|
James L L Tullis > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
5,379
-0.35%
|
$75,306
$14.67 P/Share
|
|
Jun 28
2021
|
James L L Tullis > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
10,858
-0.7%
|
$152,012
$14.98 P/Share
|
|
Jun 25
2021
|
James L L Tullis > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
8,763
-0.56%
|
$140,208
$16.03 P/Share
|
|
May 17
2021
|
Mark Hazeltine Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,934
+4.68%
|
$0
$0.26 P/Share
|
|
Feb 23
2021
|
Fortunato R. Rocca President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+50.0%
|
-
|
|
Feb 23
2021
|
Debra Zack Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
37,500
+50.0%
|
-
|
|
Feb 23
2021
|
Kamal Adawi CFO and Corporate Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
37,500
+50.0%
|
-
|
|
Feb 05
2021
|
James L L Tullis > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
3,000
-12.32%
|
$51,000
$17.0 P/Share
|
|
Jan 25
2021
|
Hunt Holdings Limited Partnership > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
28,021
-2.17%
|
$448,336
$16.01 P/Share
|
|
Jan 22
2021
|
Hunt Holdings Limited Partnership > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
23,646
-1.8%
|
$378,336
$16.07 P/Share
|
|
Jan 21
2021
|
Hunt Holdings Limited Partnership > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
50,000
-3.67%
|
$800,000
$16.01 P/Share
|
|
Jan 20
2021
|
Hunt Holdings Limited Partnership > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
30,000
-2.15%
|
$480,000
$16.13 P/Share
|
|
Jan 19
2021
|
Hunt Holdings Limited Partnership > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
30,000
-2.11%
|
$480,000
$16.0 P/Share
|
|
Jan 19
2021
|
James L L Tullis > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
257
-1.04%
|
$3,855
$15.56 P/Share
|
|
Jan 15
2021
|
James L L Tullis > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
1,014
-3.96%
|
$15,210
$15.51 P/Share
|
|
Jan 13
2021
|
James L L Tullis > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
5,729
-9.51%
|
$85,935
$15.66 P/Share
|
|
Jan 12
2021
|
Hunt Holdings Limited Partnership > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
15,000
-1.04%
|
$240,000
$16.04 P/Share
|
|
Jan 11
2021
|
Hunt Holdings Limited Partnership > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
7,394
-0.51%
|
$118,304
$16.03 P/Share
|
|
Jan 08
2021
|
Hunt Holdings Limited Partnership > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
15,186
-1.04%
|
$242,976
$16.07 P/Share
|
|
Jan 07
2021
|
Hunt Holdings Limited Partnership > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
10,000
-0.68%
|
$160,000
$16.04 P/Share
|